Publication | Closed Access

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Breast OncologyMedicinePathologyPathological Complete ResponseImmune Checkpoint InhibitorBreast CancerCancer TreatmentPhase 2Her2-enriched SubtypeOncologyRadiation Oncology